Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 51,363 Shares

Key Points

• Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma for approximately $1.57 million, reducing their ownership by 38.27% to 82,836 shares.
• Vor Biopharma's stock experienced a 0.2% decline on the recent trading day, with shares hitting $29.00 and a market capitalization of $198.65 million.
• Despite a consensus price target of $77.83, several analysts have rated Vor Biopharma poorly, with ratings ranging from "strong sell" to "buy."

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 51,363 shares of the business's stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $30.55, for a total transaction of $1,569,139.65. Following the sale, the director owned 82,836 shares in the company, valued at $2,530,639.80. This trade represents a 38.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.

Vor Biopharma Stock Down 0.2%

Shares of VOR stock traded down $0.06 during mid-day trading on Friday, hitting $29.00. 613,740 shares of the stock were exchanged, compared to its average volume of 395,121. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80. The company has a market capitalization of $198.65 million, a PE ratio of -0.11 and a beta of 2.07. The firm's fifty day moving average price is $36.55.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Vor Biopharma in the first quarter valued at $140,000. OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma in the 1st quarter valued at about $100,000. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. Money Concepts Capital Corp grew its stake in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the second quarter worth about $66,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VOR. Wall Street Zen cut Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price for the company in a report on Wednesday, September 24th. Robert W. Baird raised shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and increased their price target for the stock from $20.00 to $64.00 in a research note on Wednesday. Zacks Research lowered Vor Biopharma from a "hold" rating to a "strong sell" rating in a research report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.